Real-world efficacy and safety of 12-week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection.
Takaoka Y, Miura K, Morimoto N, Ikegami T, Kakizaki S, Sato K, Ueno T, Naganuma A, Kosone T, Arai H, Hatanaka T, Tahara T, Tano S, Ohtake T, Murohisa T, Namikawa M, Asano T, Kamoshida T, Horiuchi K, Nihei T, Soeda A, Kurata H, Fujieda T, Ohtake T, Fukaya Y, Iijima M, Watanabe S, Isoda N, Yamamoto H; Liver Investigators in the Northern Kanto Study (LINKS) group.
Takaoka Y, et al. Among authors: horiuchi k.
Hepatol Res. 2021 Jan;51(1):51-61. doi: 10.1111/hepr.13576. Epub 2020 Oct 20.
Hepatol Res. 2021.
PMID: 33021009